Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): Association of the high-enzyme activity val allele with ADHD impulsive-hyperactive phenotype
J. Eisenberg et al., Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): Association of the high-enzyme activity val allele with ADHD impulsive-hyperactive phenotype, AM J MED G, 88(5), 1999, pp. 497-502
Attention deficit hyperactivity disorder (ADHD) is a developmental syndrome
expressed along three domains: inattention, hyperactive-impulsive, and com
bined type. Both environmental and genetic factors contribute to the etiolo
gy of this complex disease. In the current investigation, a cat-echol-O-met
hyltransferase (COMT) polymorphism that codes for a high versus low enzyme
COMT activity was examined using family-based methods for a role in ADHD. U
sing a haplotype relative risk design and a parent-to-proband allele transm
ission test with 48 ADHD triads, we found an association between COMT and i
llness (chi(2) = 4.72,p = 0.03, df = 1). In particular, the impulsive-hyper
active type of ADHD (excluding inattention) ascertained by Diagnostic and S
tatistical Manual of Mental Disorders (DSM IV), criteria (chi(2) = 8.34, P
= 0.004, df = 1), by the Conners Teaching Rating Hyperactivity scale (Pears
on chi(2) = 5.32, p = 0.02, df = 1) as well as by the Continuous Performanc
e Test False Alarm scale (chi(2) = 2.78, P = 0.096, df = 1) were associated
with the high enzyme activity COMT val allele. Similar results were obtain
ed if genotype frequencies were compared. It should be noted that the assoc
iation between the high-enzyme activity COMT val allele that increases CNS
dopamine (and norepinephrine) clearance is consistent with the use of methy
lphenidate, an agent that increases dopamine (and norepinephrine) turnover,
in the treatment of this disorder. These provisional findings suggest that
newly developed COMT inhibitors such as tolcapone, applied in Parkinson's
disease, might in due time be considered in the treatment of ADHD. (C) 1999
Wiley-Liss, Inc.